Author

Ntokozo Zuma-Gwala

Institution: Setshaba Research Centre

Observed institution: Setshaba Research Centre

ORCID: 0009-0009-0395-8189

Observed ORCID: 0009-0009-0395-8189

OpenAlex ID: A5098673478

Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial

2024 · Muge Cevik, Lindsay C Thompson, et al. · The Lancet Infectious Diseases · 67

Immunogenicity and safety of a group B Streptococcus vaccine (GBS-AlpN) in pregnant women and their infants: a phase 2, multicentre, observer-blind, randomised, placebo-controlled study

2025 · Paul T Heath, Ntokozo Zuma-Gwala, et al. · The Lancet Infectious Diseases · 11

Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial

2026 · Rodney Dawson, Andreas H Diacon, et al. · The Lancet Infectious Diseases · 3

Works count: 3

Citation count: 81

H-index: 3

I10-index: 2